YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

DES Exposure May Impair Later Function of the Uterus

Mar 9, 2005 | Tulane University

A new study by Tulane University researchers, published in the March edition of Molecular Endocrinology, provides insight into one of the ways diethylstilbesterol (DES) may alter the development of the uterus.

DES, a synthetic estrogen, was prescribed to prevent miscarriage in many women who were pregnant between 1941 until 1971. In 1971, DES was banned in the United States due to concerns about the occurrence of cancer and infertility in the daughters of women who took it.

Several millions of pregnant women were treated with DES and we have continued to study and model the disease since it provides unique insights into what estrogenic chemicals may do to the developing fetus, says study co-author John McLachlan, director of the Center for Bioenvironmental Research at Tulane and Xavier Universities. There are other chemicals in our environment the results of industrial, agriculture and chemical processing that, while their estrogenic affect is weaker, may affect developing embryos in the same way. We need models to understand the cellular and genetic mechanisms by which environmental chemicals work. This study is a step in that direction.

Exposing a newborn mouse to DES may interfere with the proper development of the uterus, say Tulane University researchers. In this study, the scientists provide evidence that exposure to DES early in life can change the way genes are expressed in the uterus of mice long after the chemical treatment is stopped. This work is on the cutting edge of an area of scientific research called genetic imprinting, say the researchers.

“The results of this study and those from other labs suggest that some diseases seen in adults may have started with exposure to chemicals while in the womb, McLachlan says. This is a whole new kind of birth defect.
DES Diethylstilbestrol
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

When was DES taken?

Date of birth of person injured
(mm-dd-yyyy):

What condition was this medication prescribed to treat?

What was the name of the medication taken that contained DES?

Who has been affected by DES use (i.e. son/daughter/grandchildren)?

Have any of the following been diagnosed? (Please check all that apply.)






Please further describe side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Bad Med
 
 

News Feeds

WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News